BOSTON, Mass. — The Cannabis plant is truly remarkable, producing a broad spectrum of pharmacologically active phytochemicals, including cannabinoids, terpenoids, and phenolic compounds.
The major cannabinoids, THC and CBD, have been extensively studied in recent decades and have been shown to have therapeutic effects on the endocannabinoid system and other important signaling pathways. Animal studies and clinical trials in human subjects suggest potential benefits across a broad range of therapeutic areas, including: epilepsy, spasticity in multiple sclerosis, post-traumatic stress disorder, psychosis, chronic pain, migraine, fibromyalgia, neuroinflammation, inflammatory bowel disease, osteoporosis, osteoarthritis, and the treatment of a variety of cancer types.
This research has caused a lift of cannabis prohibition in a number of states and countries, as voters and government officials now recognize the many therapeutic benefits cannabis provides. Now more than ever, research into the safety, quality, and efficacy of cannabis is critical as these municipalities draft legislation that will regulate how the plant is produced, distributed, and consumed.
The CannMed 2017 Conference will be a gathering of the greatest minds in medical cannabis research, where they will discuss the work they are doing to better understand this remarkable plant and how their work will shape future cannabis regulations.